Pharmaceutical and diagnostics company Roche (SIX:RO) (OTCQX:RHHBY) stated on Tuesday that the US FDA EUA Elecsys Anti-SARS-CoV-2 antibody test is being used at more than 20 commercial and hospital lab sites throughout the US.

According to the company, it is working to meet demand by scaling global production rapidly in an effort to expand broader access as quickly as possible. It plans to increase to more than 200 commercial and hospital lab sites with the ability to perform two million tests per week. It has more than 3,000 analyzers that perform the antibody test installed across the US.

The company's Elecsys Anti-SARS-CoV-2 test, which is based on an in-solution double-antigen sandwich format, can detect antibodies to the new coronavirus causing COVID-19, which could signal whether a person has already been infected and potentially developed immunity to the virus. The Elecsys Anti-SARS-CoV-2 assay has 99.8% specificity and shows no cross-reactivity to the common cold, HIV and other coronaviruses. It can lower the chance of false positives due to the detection of similar antibodies that may be present in an individual.